Systems-level immunomonitoring using self-sampled capillary blood

Vijay Sai Josyula¹, Tadepally Lakshmikanth¹, Jaromir Mikes¹, Yang Chen¹, Petter Brodin^{1,2}

¹ Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet

² Department of Newborn Medicine, Karolinska University Hospital

Correspondence to: petter.brodin@ki.se

Abstract

Comprehensive profiling of the human immune system in patients with cancer, autoimmune disease and during infections are providing valuable information that help us understand disease states and discriminate productive from inefficient immune responses and identify possible targets for immune modulation. Recent technical advances now allow for all immune cell populations and hundreds of plasma proteins to be detected using small volume blood samples. To democratize such systems-immunological analyses, further simplified blood sampling and preservation will be important. Here we describe that blood obtained via a nearly painless self-sampling device of 100 microliter of capillary blood that is preserved and frozen, can simplify systems-level immunomonitoring studies.

Systems immunology involves simultaneous analyses of all immune system components and their inter-relationship in health and disease. Such analyses are revealing important patterns, previously not visible using more reductionist approaches involving individual cell populations and proteins¹. For example, we have learned in recent years that human immune systems are predominantly shaped by non-heritable factors such as Cytomegalovirus²⁻⁵, and that immune systems diverge with age as environmental exposures accumulate. We are also beginning to learn that baseline immune system states can be predictive of vaccine responses^{3,6}, and response to immunomodulatory treatments⁷. During an immune response, for example in the context of immunotherapy of cancer, signatures of immune cell changes can predict clinical outcome⁸. Finally, by longitudinal monitoring of healthy individuals we are learning how newborn immune systems are shaped early in life⁹, and how immunological changes associated with aging manifest itself and affect disease risks in the elderly¹⁰.

We have recently described that using stabilized and frozen whole blood, rather than the more commonly used viable peripheral blood mononuclear cells for immunomonitoring, offers advantages thanks to lower technical variation¹¹. and Using preserved whole blood also allow for much smaller blood volumes to be used⁹. In parallel with this, Blicharz and colleagues have developed a microneedle-device for self-sampling of capillary blood that is meant to simplify blood sampling and mitigate the fear of needles and simplify clinical blood testing¹². The system is virtually pain-free due to the use of microneedles that only sample shallow capillaries in the skin (Figure 1a-b). Here we show, that patient self-sampling of capillary blood using TAP (7sense Bio, Medford, MA, USA), in combination with whole blood stabilizer (Whole blood processing kit, Cytodelics AB, Stockholm, Sweden), and an optimized cell processing protocols¹³, allows for complete systems-level immunomonitoring. This will enable samples to be collected at home by

patients without having to visit a clinic, allowing more frequent sampling and more careful monitoring of their immune systems. We show, using Mass cytometry that system-level immune profiles are comparable to those obtained via traditional venipuncture sampling protocols, and that the blood volumes obtained by self-sampling devices are enough to capture comprehensive immune system states across all relevant immune cell populations.

To test the self-sampling system for immunomonitoring we allowed non-experts to sample themselves using the TAP-device in both of their upper arm and directly after this, they were also subject to traditional venipuncture as well as a capillary finger-prick sampling using traditional lancet. All the samples from these localities were preserved using a whole-blood stabilizer solution and frozen at -80 C and transported to the laboratory for analysis (Figure 1c). From our previous testing we know that also -20 C freezing of whole blood is possible for a limited amount of time, allowing subjects to freeze samples at home. The blood samples were barcoded together¹⁴, stained with a 48-parameter panel targeting markers in all major immune cell populations. The samples were subsequently acquired by Mass cytometry and canonical cell populations identified using a machine learning approach (Chen et al, manuscript in preparation). The results show that cell frequencies differ among the two donors as expected from the known variation among healthy human immune systems¹⁵ (Figure 1c). We conclude from this result that self-sampling using the nearly painless TAP device, in combination with whole blood stabilization and freezing can enable more broad application of systems-level immunomonitoring by allowing patients to sample themselves at home. Other important implications of this work are that patients soon will be able to sample themselves frequently in the comfort of their own home, without risking significant blood loss over time thanks to the small volumes collected with each sample, possibly increasing the temporal resolution in many immunomonitoring studies.

All in all, we have shown here that the combination of two recently developed methods for improved blood sampling now allow for advanced, systems-level immunomonitoring using minimal samples of capillary blood collected by patients themselves, with broad implications for studies in a range of patients with immune mediated disease, infections and cancer, treated with immunotherapy to name a few.

Figure 1. Systems-level immunology via a self-sampling device. a-b) Device for self-use capillary sampling, c) Stabilization of whole blood and freezing prior to Mass cytometry analysis. e) Example tSNE of a blood sample collected via TAP-capillary device, and f) relative proportions of major immune cell populations in TAP-sampled, finger prick and venipuncture sampled blood.

Methods

Blood sample collection and processing

Blood samples (~100µl) were obtained from two healthy donors from the following sites using the following devices – a) Capillary blood collection (TAP device, 7sense bio) – blood was collected from both upper left and right arms; b) Venipuncture (vacutainer blood collection tube and needle) – venous blood was drawn from the middle cubital vein in the arm; c) Fingerstick (Lancet and microvette) – blood was drawn from one of the fingertips. Each blood sample was mixed 1:1 with a blood stabilizer solution (Cytodelics AB, Stockholm), incubated for 10 min at room temperature followed by freezing at -80 C. At the time of experimentation, blood samples were thawed and fixed/lysed using Fix/Lyse buffer (Cytodelics AB) as per the manufacturer’s recommendations.

Sample multiplexing and staining

Blood samples post fix/lysis were resuspended in Wash # 2 buffer (Cytodelics) and barcoded using 20-Plex Pd Barcoding kit (Fluidigm). Samples were barcoded using the principles reported elsewhere¹⁴. A Bravo liquid handling automation platform¹³ (Agilent technologies) was used to barcode and pool samples. Briefly, each barcode was resuspended in 100ul of 1x barcode perm buffer. The cells that were resuspended in Wash # buffer and centrifuged at 500g for 5 min followed by 2 washes with 1x barcode perm buffer. Following washes, samples were resuspended in 100ul of 1x barcode perm buffer and to this the reconstituted barcodes were added, incubated for 30 min at room temperature followed by 2 washes with CyFACS buffer (PBS 1x with 0.1% BSA, 2mM EDTA and 0.05% Na-Azide) and pooled according to the sample schema.

The pooled sample batches were washed and FcR blocked, following which they were stained with a cocktail of metal-conjugated antibodies targeting surface markers. Cells were incubated at 4 C

for 30 min, washed twice using CyFACS buffer at 500g for 5 min and fixed overnight in 4% PFA (diluted in PBS) before mass cytometry analysis.

Antibodies for Mass cytometry

The monoclonal antibodies used in this study are listed in Table 1. Pre-conjugated antibodies were bought from Fluidigm if the metals were unavailable in their pure form. Other metals that were available in a pure form were purchased and conjugated to purified antibodies (obtained in carrier/protein-free buffer) using MAXPAR X8 polymer conjugation kit (Fluidigm) by following the manufacturer's protocol. The antibody concentrations were measured using NanoDrop 2000 spectrometer (Thermo Fischer Scientific) at 280nm before and after conjugation. The conjugated antibodies were then diluted 1:1 using Protein Stabilizer PBS (Candor Bioscience GmbH).

Sample acquisition by CyTOF

To cells fixed in PFA, Cell-ID Intercalator-Ir (191Ir/193Ir) (Fluidigm) diluted 1:1000 (stock 125 μ M) was added and incubated for 20 min at room temperature. Cells were washed twice with CyFACS buffer, followed by PBS, and milli Q water and resuspended in milli Q water. Cells were counted and filtered through a 35 μ m nylon mesh, diluted to 750,000 cells/ml by mixing 0.1X times with EQ™ four element calibration beads (Fluidigm) in Milli-Q water and acquired at a rate of 300-500 cells/s using a CyTOF2 (Fluidigm) mass cytometer, CyTOF software version 6.0.626 with noise reduction, a lower convolution threshold of 200, event length limits of 10-150 pushes, a sigma value of 3, and flow rate of 0.045 ml/min. All raw FCS-files are available <https://flowrepository.org/>, ID: FR-FCM-Z25W.

Data analysis

Preprocessing of data

The samples were debarcoded and relative proportion of the major cell types in each sample was obtained using an automated classification algorithm trained on manually gated training datasets (Chen et al, manuscript). The output file is a single-cell table with cells in rows and markers in columns and an annotation column showing population label according to the learning algorithm.

Statistics

The relative proportions of the cell populations of each sample was plotted as a stacked bar plot using matplotlib and the pandas libraries in python version 3.0.

Data visualization

Single-cell data were embedded by tSNE, using the R-implementation, rtsne after scaling all markers to unit variance. This was done using R version 3.6.0 (<https://www.r-project.org/>). An Aitchinson's distance matrix was calculated between all samples using their relative cell proportions as input using the aDist function. Multidimensional scaling coordinates were obtained using the cmdscale function and the resultant 2D data visualized as a scatter plot using the ggplot2 package.

Acknowledgements

V.S.J performed experiments with the help from T.LK. The study was planned by P.B, T.LK, J.M and Y.C provided data analysis support.

Conflict of interest

P.B, T.LK and J.M are cofounders and shareholders in Cytodelics AB.

References

1. Davis, M. & Brodin, P. Rebooting Human Immunology. *Annual review of immunology* **36**, 843–864 (2018).
2. Brodin, P. *et al.* Variation in the human immune system is largely driven by non-heritable influences. *Cell* **160**, 37–47 (2015).
3. Kaczorowski, K. J. *et al.* Continuous immunotypes describe human immune variation and predict diverse responses. *Proceedings of the National Academy of Sciences of the United States of America* **114**, E6097–E6106 (2017).
4. Patin, E. *et al.* Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. *Nature Immunology* 1–13 (2018). doi:10.1038/s41590-018-0049-7
5. Furman, D. *et al.* Cytomegalovirus infection enhances the immune response to influenza. *Science translational medicine* **7**, 281ra43 (2015).
6. Tsang, J. S. *et al.* Global analyses of human immune variation reveal baseline predictors of postvaccination responses. *Cell* **157**, 499–513 (2014).
7. Gaujoux, R. *et al.* Cell-centred meta-analysis reveals baseline predictors of anti-TNF α non-response in biopsy and blood of patients with IBD. *Gut* **68**, 604–614 (2019).
8. Krieg, C. *et al.* High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.

Nature medicine **24**, 144–153 (2018).

9. Olin, A. *et al.* Stereotypic Immune System Development in Newborn Children. *Cell* **174**, 1277–1292.e14 (2018).

10. Alpert, A. *et al.* A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. *Nature medicine* **25**, 487–495 (2019).

11. Brodin, P., Duffy, D. & Quintana-Murci, L. A Call for Blood-In Human Immunology. *Immunity* **50**, 1335–1336 (2019).

12. Blicharz, T. M. *et al.* Microneedle-based device for the one-step painless collection of capillary blood samples. *Nature biomedical engineering* **2**, 151–157 (2018).

13. Mikes, J., Olin, A., Lakshmikanth, T., Chen, Y. & Brodin, P. Automated Cell Processing for Mass Cytometry Experiments. *Methods in molecular biology (Clifton, N.J.)* **1989**, 111–123 (2019).

14. Zunder, E. R. *et al.* Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. *Nature protocols* **10**, 316–33 (2015).

15. Brodin, P. & Davis, M. Human immune system variation. *Nature reviews. Immunology* **17**, 21–29 (2017).

Table 1. Antibodies used for mass cytometry analysis

Metal tag	Marker	Clone	Company*
89Y	CD45	HI30	Fluidigm
102Pd	Barcode	Cell-ID™ 20-Plex Pd Barcoding Kit	Fluidigm
104Pd	Barcode		
105Pd	Barcode		
106Pd	Barcode		
108Pd	Barcode		
110Pd	Barcode		
113In	CD57	HCD57	BioLegend
115In	HLA-A, B, C	W6/32	BioLegend
141Pr	CD49d	9F10	Fluidigm
142Nd	CD19	HIB19	Fluidigm
143Nd	CD5	UCHT2	BioLegend
144Nd	CD16	3G8	BioLegend
145Nd	CD4	RPA-T4	BioLegend
146Nd	CD8a	SK1	BioLegend
147Sm	CD11c	Bu15	Fluidigm
148Nd	CD31	WM59	BioLegend
149Sm	CD25	2A3	Fluidigm
150Nd	CD64	10.1	BioLegend
151Eu	CD123	6H6	BioLegend
152Sm	TCRγδ	5A6.E9	Fischer Scientific
153Eu	Siglec-8	837535	R&D Systems
154Sm	CD3e	UCHT1	BioLegend
155Gd	CD33	WM53	BioLegend
156Gd	CD26	BA5b	BioLegend
157Gd	CD9	SN4 C3-3A2	eBiosciences
158Gd	CD34	581	BioLegend
159Tb	CD22	HIB22	BioLegend
160Gd	CD14	M5E2	BioLegend
161Dy	CD161	HP-3G10	BioLegend
162Dy	CD29	TS2/16	BioLegend
163Dy	HLA-DR	L243	BioLegend
164Dy	CD44	BJ18	BioLegend
165Ho	CD127	A019D5	Fluidigm
166Er	CD24	ML5	BioLegend
167Er	CD27	L128	Fluidigm
168Er	CD38	HIT2	BioLegend
169Tm	CD45RA	HI100	Fluidigm
170Er	CD20	2H7	BioLegend
171Yb	CD7	CD7-6B7	BioLegend
172Yb	IgD	IA6-2	BioLegend
173Yb	CD56	NCAM16.2	BD

174Yb	CD99	HCD99	BioLegend
175Lu	CD15	W6D3	BioLegend
176Yb	CD39	A1	BioLegend
191Ir	DNA-Ir	Cell-ID™ Intercalator-Ir	Fluidigm
193Ir			
209Bi	CD11b	Mac-1	Fluidigm

** All antibodies other than those purchased from Fluidigm have been coupled in-house*